Clinical Trial Outcomes Risk: Veru's future depends heavily on the successful completion of clinical trials for its drug candidates, such as sabizabulin in oncology and enobosarm for specific breast cancer indications, and the achievement of primary and secondary endpoints. Failure at any stage could significantly delay or prevent commercialization and negatively impact the company's valuation.

Regulatory Approval Hurdles Risk: Even with positive clinical trial results, Veru may fail to obtain necessary regulatory approvals from agencies like the FDA or EMA for its drug candidates. Regulatory bodies may require additional studies, deem the data insufficient, or identify safety concerns, leading to delays or outright rejection, as seen previously with sabizabulin for COVID-19.

Commercialization Challenges Risk: If Veru's drug candidates receive regulatory approval, the company faces significant challenges in successfully marketing, distributing, and achieving market acceptance for its products. This includes building an effective sales force, competing with established therapies, and securing favorable reimbursement policies from payers.